OBIO
NASDAQOrchestra BioMed Holdings Inc.
Price$4.03+0.06 (+1.51%)
01:30 PM07:45 PM
News · 26 weeks480%
2025-12-142026-06-07
Mix2890d
- Insider13(46%)
- Other10(36%)
- SEC Filings5(18%)
Latest news
25 items- INSIDEROfficer Hochman David P bought $19,150 worth of shares (5,000 units at $3.83), increasing direct ownership by 0.47% to 1,064,029 units (SEC Form 4)4 - Orchestra BioMed Holdings, Inc. (0001814114) (Issuer)
- INSIDEROfficer Sherman Darren sold $58,050 worth of shares (15,000 units at $3.87) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 1,184,327 units (SEC Form 4)4 - Orchestra BioMed Holdings, Inc. (0001814114) (Issuer)
- PROrchestra BioMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NEW HOPE, Pa., June 02, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) ("Orchestra BioMed" or the "Company"), a biomedical company accelerating high-impact technologies to patients through strategic partnerships with market-leading global medical device companies, reported today that, on June 1, 2026, the Compensation Committee of the Orchestra BioMed Board of Directors granted stock options to purchase an aggregate of 85,500 shares of the Company's common stock to five newly hired employees. The awards were granted pursuant to the Orchestra Biomed Holdings, Inc. 2025 New Hire Inducement Plan as an inducement material to each new employee entering employment with Or
- SECSEC Form 144 filed by Orchestra BioMed Holdings Inc.144 - Orchestra BioMed Holdings, Inc. (0001814114) (Subject)
- INSIDERChief Financial Officer Taylor Andrew Lawrence covered exercise/tax liability with 3,076 shares, decreasing direct ownership by 0.49% to 629,417 units (SEC Form 4) (for tax liability)4 - Orchestra BioMed Holdings, Inc. (0001814114) (Issuer)
- INSIDEROfficer Sherman Darren covered exercise/tax liability with 4,925 shares, decreasing direct ownership by 0.41% to 1,199,327 units (SEC Form 4) to satisfy tax liability4 - Orchestra BioMed Holdings, Inc. (0001814114) (Issuer)
- INSIDERDirector Aryeh Jason bought $2,494 worth of shares (665 units at $3.75), increasing direct ownership by 0.57% to 118,118 units (SEC Form 4)4 - Orchestra BioMed Holdings, Inc. (0001814114) (Issuer)
- PROrchestra BioMed to Participate in the Jefferies Global Healthcare ConferenceNEW HOPE, Pa., May 19, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO, "Orchestra BioMed" or the "Company")), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced that company management will be participating in the Jefferies Global Healthcare Conference. Chairman and CEO David Hochman will participate in a fireside chat with Matt Taylor, Managing Director at Jefferies at 9:55am ET on Thursday June 4, 2026 and will also host one-on-one meetings with investors that day and on Wednesday, June 3. The fireside chat will be accessible to investors and interested parties via a live webcast, which
- INSIDEROfficer Hochman David P bought $18,850 worth of shares (5,000 units at $3.77), increasing direct ownership by 0.47% to 1,059,029 units (SEC Form 4)4 - Orchestra BioMed Holdings, Inc. (0001814114) (Issuer)
- INSIDERDirector Aryeh Jason bought $34,987 worth of shares (8,971 units at $3.90), increasing direct ownership by 8% to 117,453 units (SEC Form 4)4 - Orchestra BioMed Holdings, Inc. (0001814114) (Issuer)
- INSIDERDirector Fain Eric S bought $82,600 worth of shares (20,000 units at $4.13) (SEC Form 4)4 - Orchestra BioMed Holdings, Inc. (0001814114) (Issuer)
- PROrchestra BioMed Reports First Quarter 2026 Financial Results and Highlights Recent Business UpdatesOrchestra BioMed targeting enrollment completion of BACKBEAT Global Pivotal Trial ("BACKBEAT Trial") by the end of Q3 2026Medtronic (NYSE:MDT) and Orchestra BioMed intend to pursue late-breaking clinical trial presentation at major cardiology conference in Q2 2027 and subsequent marketing application submission to FDA and global regulatory agencies, assuming primary endpoints are met FDA granted a second Breakthrough Device Designation ("BDD") for AVIM Therapy specific to patients with uncontrolled hypertension despite the use of anti-hypertensive medications, and an indication for a pacemakerVirtue Trial sites progressing with site activation and patient enrollment acceleration continuing t
- SECSEC Form 10-Q filed by Orchestra BioMed Holdings Inc.10-Q - Orchestra BioMed Holdings, Inc. (0001814114) (Filer)
- PROrchestra BioMed Targeting BACKBEAT Trial Enrollment Completion By End of Q3 2026 and Data Presentation in Q2 2027Orchestra BioMed targeting enrollment completion of BACKBEAT Global Pivotal Trial ("BACKBEAT Trial") by the end of Q3 2026 Orchestra BioMed and Medtronic plc. (NYSE:MDT, "Medtronic")), the Company's strategic collaborator for the BACKBEAT Trial, intend to submit primary endpoint results for consideration as a late-breaker at a major cardiology conference in Q2 2027Medtronic plans to submit AVIM Therapy-related marketing application for FDA approval after primary endpoint data analyses and reports are complete and pursue subsequent global regulatory approvals, assuming primary safety and efficacy endpoints are met NEW HOPE, Pa., May 12, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, I
- PROrchestra BioMed Receives $15 Million Investment from Ligand Under Previously Announced Strategic Financing Agreement$15 million payment fulfills previously scheduled tranche under royalty-based financing agreement, bringing total capital received from Ligand to $40 million to date in exchange for tiered royalty interest in Orchestra BioMed's future revenue as well as equityFunding supports continued execution of Orchestra BioMed's pivotal trials for Atrioventricular Interval Modulation Therapy ("AVIM Therapy") and Virtue Sirolimus AngioInfusion Balloon ("Virtue SAB") This payment, together with a $20 million investment from Medtronic (NYSE:MDT) announced separately, represents a total of $35 million in fresh strategic capital received on May 1, 2026 under previously disclosed agreements NEW HOPE, Pa., Ma
- PROrchestra BioMed Receives $20 Million Payment from Medtronic Under Previously Announced Financing AgreementPayment fulfills previously disclosed funding commitment of $20 million and supports planned completion of the BACKBEAT Global Pivotal Trial ("BACKBEAT Trial") evaluating Atrioventricular Interval Modulation Therapy ("AVIM Therapy") in patients with uncontrolled hypertension and an indication for a pacemaker as part of the strategic collaboration between Orchestra BioMed and MedtronicThis payment, together with $15 million received from Ligand and announced separately, represents a total of $35 million in strategic capital received under previously disclosed agreements NEW HOPE, Pa., May 06, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) ("Orchestra BioMed" or the
- PRFDA Grants Orchestra BioMed Additional Breakthrough Device Designation for AVIM TherapyAtrioventricular Interval Modulation ("AVIM") Therapy Food and Drug Administration ("FDA") Breakthrough Device Designations span the broader population of patients with uncontrolled hypertension despite medication at increased cardiovascular risk and the specific pacemaker-indicated population being evaluated in the BACKBEAT TrialThe addressable U.S. patient population for AVIM Therapy, based on the indications for use specified in its Breakthrough Device Designations, comprises over 7.7 million adults with hypertension despite medicationBreakthrough Device Designation supports favorable reimbursement pathways, including potential eligibility for New Technology Add-on Payment ("NTAP") and Tr
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Orchestra BioMed Holdings Inc.SCHEDULE 13D/A - Orchestra BioMed Holdings, Inc. (0001814114) (Subject)
- INSIDERLarge owner Rtw Investments, Lp exercised 1,250,032 in-the-money shares at a strike of $0.00 and sold $132 worth of shares (32 units at $4.13) (SEC Form 4)4 - Orchestra BioMed Holdings, Inc. (0001814114) (Issuer)
- SECSEC Form DEFA14A filed by Orchestra BioMed Holdings Inc.DEFA14A - Orchestra BioMed Holdings, Inc. (0001814114) (Filer)
- SECSEC Form DEF 14A filed by Orchestra BioMed Holdings Inc.DEF 14A - Orchestra BioMed Holdings, Inc. (0001814114) (Filer)
- PROrchestra BioMed to Present AVIM Therapy Clinical and Mechanistic Data at HRS 2026Pre-randomization Atrioventricular Interval Modulation Therapy ("AVIM Therapy") set-up data from the MODERATO II randomized, prospective, multi-center, double-blind, controlled trial show an immediate average reduction of 13.2 mmHg in office systolic blood pressure ("oSBP")97% of patients experienced an immediate blood pressure reduction of >5 mmHg reduction in oSBP prior to randomizationAVIM Therapy demonstrated the potential to deliver immediate, substantial, and sustained reductions in blood pressure, with evidence of improved diastolic function and reverse cardiac remodelingThe BACKBEAT Global Pivotal Trial, which Orchestra BioMed is actively enrolling as part of a strategic collaboratio
- INSIDERSEC Form 4 filed by Sherman Darren4 - Orchestra BioMed Holdings, Inc. (0001814114) (Issuer)
- INSIDERSEC Form 4 filed by Aiello Joshua4 - Orchestra BioMed Holdings, Inc. (0001814114) (Issuer)
- INSIDERSEC Form 4 filed by Hochman David P4 - Orchestra BioMed Holdings, Inc. (0001814114) (Issuer)
OBIO FAQ
6 questionsWhere does OBIO stock trade?
Orchestra BioMed Holdings Inc. (OBIO) is listed on NASDAQ.What sector and industry is OBIO in?
Orchestra BioMed Holdings Inc. operates in the Health Care sector, Medicinal Chemicals and Botanical Products industry.When did Orchestra BioMed Holdings Inc. go public?
Orchestra BioMed Holdings Inc. (OBIO) completed its IPO in 2020.What are analysts saying about OBIO?
Orchestra BioMed Holdings Inc. has had 8 recent analyst actions on file. The most recent action was from TD Cowen: Buy with a $1500.00 price target on 2025-12-10. Recent price targets range from $1200.00 to $1600.00.What companies are similar to OBIO?
Notable peers in the same industry include PM (Philip Morris International Inc), BTI (British American Tobacco Industries p.l.c.), MO (Altria Group Inc.), RGC (Regencell Bioscience Holdings Limited), RLX (RLX Technology Inc.). Compare OBIO side-by-side with any of them on Quantisnow.How can I track OBIO on Quantisnow?
Quantisnow aggregates Orchestra BioMed Holdings Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow OBIO to receive live email and push alerts on every new disclosure.